Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease

References

• Centers for Disease Control and PreventionNational diabetes statistics report: estimates of diabetes and its burden in the United States, 2014 Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdfAccessed September 23, 2014
   Google Scholar
• GersteinHCMannJFYiQAlbuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individualsJAMA2001286442142611466120
   PubMed Web of Science ®Google Scholar
• MokdadAHFordESBowmanBAPrevalence of obesity, diabetes, and obesity-related health risk factors, 2001JAMA20032891767912503980
   PubMed Web of Science ®Google Scholar
• MooradianADDyslipidemia in type 2 diabetes mellitusNat Clin Pract Endocrinol Metab20095315015919229235
   PubMedGoogle Scholar
• EngelgauMMGeissLSSaaddineJBThe evolving diabetes burden in the United StatesAnn Intern Med20041401194595015172919
   PubMed Web of Science ®Google Scholar
• FoxCSCoadySSorliePDIncreasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart StudyCirculation2007115121544155017353438
   PubMed Web of Science ®Google Scholar
• HuFBStampferMJHaffnerSMSolomonCGWillettWCMansonJEElevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetesDiabetes Care20022571129113412087009
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionNational diabetes fact sheet, 2011: national estimates and general information on diabetes and prediabetes in the United States Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdfAccessed August 14, 2014
   Google Scholar
• GersteinHCSwedbergKCarlssonJThe hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programArch Intern Med2008168151699170418695086
   PubMedGoogle Scholar
• SelvinEMarinopoulosSBerkenblitGMeta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitusAnn Intern Med2004141642143115381515
   PubMed Web of Science ®Google Scholar
• SelvinESteffesMWZhuHGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adultsN Engl J Med2010362980081120200384
   PubMed Web of Science ®Google Scholar
• DuckworthWAbrairaCMoritzTGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med2009360212913919092145
   PubMed Web of Science ®Google Scholar
• GersteinHCMillerMEByingtonRPEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• PatelAMacMahonSChalmersJIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med2008358242560257218539916
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• RayKKSeshasaiSRWijesuriyaSEffect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trialsLancet200937396771765177219465231
   PubMed Web of Science ®Google Scholar
• GaedePLund-AndersenHParvingHHPedersenOEffect of a multifactorial intervention on mortality in type 2 diabetesN Engl J Med2008358658059118256393
   PubMed Web of Science ®Google Scholar
• GaedePVedelPLarsenNJensenGVParvingHHPedersenOMultifactorial intervention and cardiovascular disease in patients with type 2 diabetesN Engl J Med2003348538339312556541
   PubMed Web of Science ®Google Scholar
• GoodCBPolypharmacy in elderly patients with diabetesDiabetes Spectrum2002154240248
   Google Scholar
• CurkendallSMThomasNBellKFJuneauPLWeissAJPredictors of medication adherence in patients with type 2 diabetes mellitusCurr Med Res Opin201329101275128623815104
   PubMed Web of Science ®Google Scholar
• GarberAJAbrahamsonMJBarzilayJIAmerican Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement – executive summaryEndocr Pract201319353655723816937
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• DruckerDJThe role of gut hormones in glucose homeostasisJ Clin Invest20071171243217200703
   PubMed Web of Science ®Google Scholar
• FrederichRMcNeillRBerglindNFlemingDChenRThe efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trialDiabetol Metab Syndr2012413622828124
   PubMed Web of Science ®Google Scholar
• RosenstockJAguilar-SalinasCKleinENepalSListJChenREffect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetesCurr Med Res Opin200925102401241119650754
   PubMed Web of Science ®Google Scholar
• DeFronzoRAHissaMNGarberAJThe efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneDiabetes Care20093291649165519478198
   PubMed Web of Science ®Google Scholar
• ChacraARTanGHApanovitchARavichandranSListJChenRSaxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trialInt J Clin Pract20096391395140619614786
   PubMed Web of Science ®Google Scholar
• HollanderPLiJAllenEChenRCV181-013 InvestigatorsSaxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione aloneJ Clin Endocrinol Metab200994124810481919864452
   PubMed Web of Science ®Google Scholar
• BarnettAHCharbonnelBDonovanMFlemingDEffect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metforminCurr Med Res Opin201228451352322313154
   PubMed Web of Science ®Google Scholar
• AmoriRELauJPittasAGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJAMA2007298219420617622601
   PubMed Web of Science ®Google Scholar
• KaragiannisTPaschosPPaletasKMatthewsDRTsapasADipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysisBMJ2012344e136922411919
   PubMed Web of Science ®Google Scholar
• CookWBryzinskiBSlaterJFrederichRAllenESaxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trialsPostgrad Med2013125314515423748515
   PubMed Web of Science ®Google Scholar
• MinerviniGCookWAllenEEfficacy and tolerability of saxagliptin in patients with type 2 diabetes mellitus and a history of cardiovascular diseaseDiabetes201362Suppl 1A306
   Google Scholar
• JadzinskyMPfutznerAPaz-PachecoEXuZAllenEChenRSaxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trialDiabetes Obes Metab200911661162219515181
   PubMed Web of Science ®Google Scholar
• GökeBGallwitzBErikssonJHellqvistAGause-NilssonISaxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trialInt J Clin Pract201064121619163120846286
   PubMed Web of Science ®Google Scholar
• CookWBryzinskiBAllenEHirshbergBSaxagliptin (SAXA) efficacy and safety in patients with type 2 diabetes mellitus (T2DM) stratified by cardiovascular (CV) risk factorsEndocr Rev201334SUN-849
   Google Scholar
• D’AgostinoRBSrVasanRSPencinaMJGeneral cardiovascular risk profile for use in primary care: the Framingham Heart StudyCirculation2008117674375318212285
   PubMed Web of Science ®Google Scholar
• BonoraEAllenEBryzinskiBHirshbergBCookWSaxagliptin reduces HbA1c and is well tolerated in patients with type 2 diabetes and high Framingham 10-year cardiovascular riskDiabetes201362Suppl 1A295
   Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2014Diabetes Care201437Suppl 1S14S8024357209
   PubMed Web of Science ®Google Scholar
• GrantRWMeigsJBPrevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reductionDiabetes Care200730347948417327308
   PubMed Web of Science ®Google Scholar
• BryzinskiBAllenECookWHirshbergBSaxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapyJ Diabetes Complications7172014 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• PanCYYangWTouCGause-NilssonIZhaoJEfficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trialDiabetes Metab Res Rev201228326827522081481
   PubMed Web of Science ®Google Scholar
• KumarKMPJainSTouCSchützerKMSaxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical studyInt J Diabetes Dev Ctries201419
   Web of Science ®Google Scholar
• YangWPanCYTouCZhaoJGause-NilssonIEfficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trialDiabetes Res Clin Pract201194221722421871686
   PubMed Web of Science ®Google Scholar
• HermansMPDelibasiTFarmerIEffects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT studyCurr Med Res Opin201228101635164523020253
   PubMed Web of Science ®Google Scholar
• NowickiMRychlikIHallerHWarrenLSuchowerLGause-NilssonISaxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairmentDiabetes Obes Metab201113652353221332627
   PubMed Web of Science ®Google Scholar
• NowickiMRychlikIHallerHLong-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety studyInt J Clin Pract201165121230123921977965
   PubMed Web of Science ®Google Scholar
• RosenstockJSankohSListJFGlucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetesDiabetes Obes Metab200810537638618355324
   PubMed Web of Science ®Google Scholar
• HenryRRSmithSRSchwartzSLEffects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetesDiabetes Obes Metab201113985085821554520
   PubMed Web of Science ®Google Scholar
• ScheenAJCharpentierGOstgrenCJHellqvistAGause-NilssonIEfficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitusDiabetes Metab Res Rev201026754054920824678
   PubMed Web of Science ®Google Scholar
• StenlofKRazINeutelJRavichandranSBerglindNChenRSaxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metforminCurr Med Res Opin201026102355236320804445
   PubMed Web of Science ®Google Scholar
• WhiteJLBuchananPLiJFrederichRA randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapyBMC Endocr Disord20141411724565221
   PubMedGoogle Scholar
• NeutelJMZhaoCKaryekarCSAdding saxagliptin to metformin extended release (XR) or uptitration of metformin XR: efficacy on daily glucose measuresDiabetes Ther20134226928323881432
   PubMed Web of Science ®Google Scholar
• FonsecaVZhuTKaryekarCHirshbergBAdding saxagliptin to extended-release metformin vs. uptitrating metformin dosageDiabetes Obes Metab201214436537122192246
   PubMed Web of Science ®Google Scholar
• TzoulakiIMolokhiaMCurcinVRisk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research databaseBMJ2009339b473119959591
   PubMed Web of Science ®Google Scholar
• RydenLGrantPJAnkerSDESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on Diabetes, Pre-diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)Eur Heart J201334393035308723996285
   PubMed Web of Science ®Google Scholar
• EngelSSRoundEGolmGTKaufmanKDGoldsteinBJSafety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studiesDiabetes Ther20134111914523700194
   PubMed Web of Science ®Google Scholar
• Ligueros-SaylanMFoleyJESchweizerACouturierAKothnyWAn assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trialsDiabetes Obes Metab201012649550920518805
   PubMed Web of Science ®Google Scholar
• SchernthanerGBarnettAHEmserASafety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitusDiabetes Obes Metab201214547047822268497
   PubMed Web of Science ®Google Scholar
• Williams-HermanDEngelSSRoundESafety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetesBMC Endocr Disord201010720412573
   PubMed Web of Science ®Google Scholar
• MonamiMAhrenBDicembriniIMannucciEDipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trialsDiabetes Obes Metab201315211212022925682
   PubMed Web of Science ®Google Scholar
• HirshbergBParkerAEdelbergHDonovanMIqbalNSafety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitusDiabetes Metab Res Rev201430755656924376173
   PubMed Web of Science ®Google Scholar
• IqbalNParkerAFrederichRDonovanMHirshbergBAssessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trialsCardiovasc Diabetol2014133324490835
   PubMed Web of Science ®Google Scholar
• HirshbergBRazIImpact of the US Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugsDiabetes Care201134Suppl 2S101S10621525438
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
   PubMed Web of Science ®Google Scholar
• WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327133523992602
   PubMed Web of Science ®Google Scholar
• WhiteWBCardiovascular outcomes with alogliptin in patients with type 2 diabetes mellitus and recent acute coronary syndromesPresented at the European Association for the Study of Diabetes annual meetingSeptember 23–27, 2013Barcelona, Spain
   Google Scholar
• FadiniGPBoscaroEAlbieroMThe oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1αDiabetes Care20103371607160920357375
   PubMed Web of Science ®Google Scholar
• MatsubaraJSugiyamaSAkiyamaEDipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetesCirc J20137751337134423386232
   PubMed Web of Science ®Google Scholar
• van PoppelPCNeteaMGSmitsPTackCJVildagliptin improves endothelium-dependent vasodilatation in type 2 diabetesDiabetes Care20113492072207721788633
   PubMed Web of Science ®Google Scholar
• MonamiMLamannaCDesideriCMMannucciEDPP-4 inhibitors and lipids: systematic review and meta-analysisAdv Ther2012291142522215383
   PubMed Web of Science ®Google Scholar